Tebentafusp Trial
Phase 3
540
about 5.6 years
18+
25 sites in AZ, FL, GA +15
What this study is about
Researchers are testing whether tebentafusp, alone or with pembrolizumab, is more effective than the treatment chosen by doctors (investigator's choice) for people with advanced melanoma that has not responded to other treatments. The trial will last about 2 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Investigators Choice
- 2.Take Tebentafusp
- 3.Take Tebentafusp with Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer), tebentafusp
infusion
Primary: Overall Survival (OS)
Secondary: Change from Baseline in Circulating Tumor DNS (ctDNA), Number of participants with Grade ≥2 cytokine release syndrome (CRS), Number of participants with dose interruptions, reductions, and discontinuations from study therapy due to AEs, Number of participants with ≥1 adverse event (AE), Number of participants with ≥1 serious adverse event (SAEs), Responses to the EORTC Core Quality of Life (EORTC-QLQ-C30), Responses to the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)
Oncology